Proteasomes, the cellular machinery responsible for breaking down proteins, have long been recognised for their role in immune surveillance. But new research has uncovered an additional function that could revolutionise the understanding of how cells defend against infection. Scientists have identified proteasome-derived defence peptides that act as antimicrobial agents, providing an innate form of protection against bacterial pathogens. The findings were published in the journal Nature.
This discovery challenges the prevailing view that the primary role of proteasomes is limited to antigen presentation in adaptive immunity. The study reveals that as proteasomes degrade proteins, they generate small peptides that can directly disrupt bacterial membranes. These peptides act as a first line of defence, preventing the proliferation of harmful bacteria before the adaptive immune response is activated.
Researchers used advanced computational analysis to predict proteasomal cleavage patterns across the human proteome. The findings suggest that hundreds of thousands of these defence peptides could be generated within cells, many of which possess cationic properties that enable them to interact with and neutralise bacterial threats. Experimental evidence further supports this, demonstrating that bacterial infection triggers changes in proteasome function, enhancing the production of these peptides. This response involves the recruitment of PSME3, a proteasome activator that promotes the cleavage of peptides with increased antimicrobial activity.
The implications of these findings extend beyond basic immunology. The identification of proteasome-derived defence peptides opens up new possibilities for antibiotic development. Unlike conventional antibiotics, which are often associated with bacterial resistance, these peptides are naturally produced by human cells, potentially reducing the likelihood of resistance emerging. Their endogenous nature could also mean fewer side effects compared to synthetic antimicrobial agents.
Further investigation into the mechanisms that regulate these peptides may provide insight into their role in immune-related disorders. Previous studies have linked proteasomal dysfunction to conditions such as autoimmune diseases and cancer. If proteasome-derived defence peptides contribute to immune regulation beyond their antimicrobial activity, they may hold the key to novel therapeutic strategies for a range of diseases.
The study also raises questions about the evolutionary significance of proteasomes in immunity. While proteasomes are known for their involvement in antigen processing, this newly discovered function suggests that their role in immune defence predates adaptive immunity. The ability to generate antimicrobial peptides through protein degradation may have been a fundamental evolutionary advantage, allowing early organisms to combat infections before the development of complex immune systems.
These findings pave the way for a new understanding of the immune system, highlighting the multifaceted roles of proteasomes. Future research is expected to focus on identifying specific proteasome-derived peptides with the highest antimicrobial potential. Understanding how these peptides are regulated within cells could lead to new approaches for enhancing immune function, particularly in individuals with compromised immunity.
